Zobrazeno 1 - 10
of 50
pro vyhledávání: '"J, Maares"'
Publikováno v:
Clinical and Experimental Dermatology. 37:712-717
Summary Background. In a previous large trial (Benefit of Alitretinoin in Chronic Hand Eczema; BACH), 47.7% of patients with severe chronic hand eczema (CHE) who received alitretinoin 30 mg achieved ‘clear’ or ‘almost clear’ hands during the
Publikováno v:
Clinical and Experimental Dermatology. 36:18-23
Summary Background. Previous studies have shown that concomitant administration of food may enhance the bioavailability of oral retinoids. Aim. To assess the influence of food on the pharmacokinetics (PK) of alitretinoin after a single oral dose. Met
Autor:
B. Roos, David J. Edwards, A. H. Schmitt-Hoffmann, Pieter Jan Coenraads, J. Sauer, J. van de Wetering, K. Stoeckel, J. Maares, J. Spickermann
Publikováno v:
Clinical and Experimental Dermatology. 36:29-34
P>Background. Recent studies have found that alitretinoin can induce clinically significant responses in subjects with severe chronic hand eczema (CHE) unresponsive to topical corticosteroids. Aims. To assess the pharmacokinetics (PK), efficacy and s
Publikováno v:
Clinical and Experimental Dermatology. 36:24-28
Summary Background. Based on in vitro data with isolated cytochrome P450 (CYP) isoenzymes, alitretinoin interacts only with CYP3A4, and the potential for drug–drug interactions is considered negligible. Aim. To confirm in humans the lack of potenti
Autor:
I Meyer, B. Roos, J. Maares, J. Sauer, T. Brown, M. Schleimer, A. H. Schmitt-Hoffmann, E. Weidekamm
Publikováno v:
Clinical and Experimental Dermatology. 36:12-17
Summary Background. Alitretinoin, like all retinoids, is teratogenic, and can only be given to women of childbearing potential if pregnancy is excluded and a strict contraceptive programme is followed. Aim. This study was designed to determine whethe
Autor:
P. T. Leese, J. Sauer, M. Schleimer, J. Maares, E. Weidekamm, B. Roos, A. H. Schmitt-Hoffmann, A. Schoetzau
Publikováno v:
Clinical and Experimental Dermatology. 36:4-11
BACKGROUND: Alitretinoin (9-cis retinoic acid) is currently registered in many European countries and in Canada as the only licensed treatment for severe chronic hand eczema unresponsive to potent topical corticosteroids. Alitretinoin like all retino
Autor:
John S. C. English, Thomas A. Luger, J. Maares, Howard I. Maibach, Robin A.C. Graham-Brown, Robert Bissonnette, Thomas L. Diepgen, Bernhard Homey, Charles Lynde, Peter Elsner
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. 24:1-20
Autor:
T. C. Brown, T. Ruzicka, B. Gerlach, Margitta Worm, J. Maares, Frédéric Cambazard, Lyn Guenther, Robert Bissonnette
Publikováno v:
British Journal of Dermatology. 162:420-426
Summary Background Patients with severe chronic hand eczema (CHE) often respond to therapy with oral alitretinoin (9-cis retinoic acid). However, the efficacy of alitretinoin after disease relapse has not been demonstrated. Objectives To assess the e
Publikováno v:
Contact Dermatitis. 61:39-45
Background: The assessment of patient-relevant treatment benefit gains importance in treatment evaluation. The ‘Patient Benefit Index’ (PBI) is a validated instrument for the assessment of such benefits in patients with skin diseases. Patients ra
Autor:
T. C. Brown, Gregor B.E. Jemec, Robert Bissonnette, Charles Lynde, M Harsch, Filippa Nyberg, Åke Svensson, J. Maares, P Hollo, Thomas L. Diepgen, Thomas Ruzicka, E. Varjonen, P.-J. Coenraads, Frédéric Cambazard, M Lahfa, J. Berth-Jones, Peter Elsner, A Kaszuba
Publikováno v:
BRITISH JOURNAL OF DERMATOLOGY, 158(4), 808-817. Wiley
Background Patients with severe chronic hand eczema (CHE) refractory to topical corticosteroids currently have limited treatment options suited for chronic use, and few controlled clinical studies have investigated new therapies in this setting.Objec